image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Peter Lawson, D. Phil.
Barclays
Robert Burns
H.C. Wainwright & Co
Eric W. Joseph, Ph.D.
J.P. Morgan
Terence C Flynn, Ph.D.
Morgan Stanley & Co. LLC
Gil Blum, Ph.D.
Needham & Co.
Matthew Biegler
Oppenheimer
Gregory Renza, M.D.
RBC Capital Markets
Joel Beatty, M.D., C.F.A.
Robert W. Baird & Co
Stephen D. Willey
Stifel
Christopher Liu, Pharm.D.
SVB Leerink
Joseph M. Catanzaro, Ph.D.
Piper Sandler
Derek C. Archila
Wells Fargo Securities, LLC

Nurix Therapeutics, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Nurix Therapeutics, Inc. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Nurix Therapeutics, Inc. or its management. Nurix Therapeutics, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Print Page
Email Alerts
RSS Feeds
Contact IR